Benlysta (Belimumab) Patent Expiration, LOE Window & CMS Spending

Benlysta (Belimumab) by Human Genome Sciences: Biologic BLA (Purple Book Regime), 0 AB generics, $446.1M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHuman Genome Sciences
FDA Application & PathwayB125370 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$446.1M
2024 Medicare Part D Spend$216.8M
2024 Medicaid Spend$229.3M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 21.6% 2-yr change)